Oncorad Group, a leading player in cancer treatment across Morocco and Africa, has taken a major step forward in advancing personalized medicine. The group has entered into a strategic partnership with UM6P CoreLabs, the genetics research facility at Mohammed VI Polytechnic University. The goal of this collaboration is to establish a sustainable, high-level genetic testing infrastructure within Morocco itself.
For years, Oncorad has been incorporating genetic testing into its treatment protocols to tailor care to the unique biological profiles of each patient. This approach, which follows global best practices, enables more precise and effective management of cancer cases. It benefits not only patients directly treated by Oncorad’s facilities, but also those referred by public and private hospitals across the country.
As demand for genetic testing has continued to grow, Oncorad identified a critical challenge: Morocco’s reliance on foreign laboratories. This dependency often meant longer wait times, higher expenses, and more complex coordination in patient care.
To tackle this issue, Oncorad has decided to build a local medical genetics offering by leveraging the advanced technological capabilities of UM6P CoreLabs. Thanks to this collaboration, Morocco now has the capacity to carry out high-level genetic analyses within its own borders—delivering faster results, maintaining quality standards, and reducing overall costs.
With this new setup, healthcare providers can now order genetic tests that are performed domestically, significantly shortening turnaround times. This not only improves the clinical interpretation of results, but also allows for quicker treatment adjustments—an essential advantage in cancer care.
For patients, the shift means faster responses from doctors, lower costs that reflect the local economic context, and stronger continuity in treatment. Having the testing done nearby also helps build greater trust in medical decisions and reinforces the doctor-patient relationship.
But Oncorad’s efforts don’t stop at testing. This move is part of a broader strategy aimed at building a national ecosystem for precision medicine. The group is actively involved in developing biological and clinical data repositories, launching applied research initiatives, and training a new generation of healthcare professionals in specialized fields.
This ambitious approach reinforces Oncorad’s role as a pioneer of medical innovation in Morocco. The group is committed to creating sustainable, homegrown healthcare solutions that meet international standards while being rooted in the country’s specific needs and realities.
